NSE - Delayed Quote INR

Aarti Drugs Limited (AARTIDRUGS.NS)

462.15
-1.10
(-0.24%)
At close: 3:30:02 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Total Revenue
23,870,300
23,870,300
25,285,800
27,055,678
24,886,458
Cost of Revenue
15,421,000
15,421,000
16,777,200
22,225,987
19,849,832
Gross Profit
8,449,300
8,449,300
8,508,600
4,829,691
5,036,626
Operating Expense
6,136,500
6,136,500
5,858,500
2,166,196
2,058,657
Operating Income
2,312,800
2,312,800
2,650,100
2,663,495
2,977,969
Net Non Operating Interest Income Expense
-358,700
-358,700
-335,200
-364,388
-231,909
Pretax Income
2,117,700
2,117,700
2,355,300
2,241,821
2,699,551
Tax Provision
436,700
436,700
639,400
578,249
649,593
Net Income Common Stockholders
1,681,600
1,681,600
1,714,200
1,663,088
2,050,386
Diluted NI Available to Com Stockholders
1,681,600
1,681,600
1,714,200
1,663,088
2,050,386
Basic EPS
18.35
18.35
18.56
17.97
22.14
Diluted EPS
18.35
18.35
18.56
17.97
22.14
Basic Average Shares
91,270
91,270
91,940
92,600
92,600
Diluted Average Shares
91,270
91,270
91,940
92,600
92,600
Rent Expense Supplemental
--
--
600
600
600
Total Expenses
21,557,500
21,557,500
22,635,700
24,392,183
21,908,489
Net Income from Continuing & Discontinued Operation
1,681,600
1,681,600
1,714,200
1,663,088
2,050,386
Normalized Income
1,681,600
1,681,600
1,714,200
1,674,445.84
2,063,193.28
Interest Income
--
--
24,955
6,992
7,169
Interest Expense
358,700
358,700
335,200
332,932
207,480
Net Interest Income
-358,700
-358,700
-335,200
-364,388
-231,909
EBIT
2,476,400
2,476,400
2,690,500
2,574,753
2,907,031
EBITDA
3,034,200
3,034,200
3,205,000
3,077,995
3,407,520
Reconciled Cost of Revenue
15,421,000
15,421,000
16,777,200
22,225,987
19,849,832
Reconciled Depreciation
557,800
557,800
514,500
503,241
500,489
Net Income from Continuing Operation Net Minority Interest
1,681,600
1,681,600
1,714,200
1,663,088
2,050,386
Total Unusual Items Excluding Goodwill
0
0
0
-15,305
-16,865
Total Unusual Items
0
0
0
-15,305
-16,865
Normalized EBITDA
3,034,200
3,034,200
3,205,000
3,093,300
3,424,385
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
-3,947.16
-4,057.72
3/31/2022 - 9/19/2003

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AARTIPHARM.NS Aarti Pharmalabs Limited
909.25
-1.73%
 
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,590.20
+0.34%
 
SHILPAMED.NS Shilpa Medicare Limited
914.45
+1.75%
 
BAJAJHCARE.NS Bajaj HealthCare Limited
526.80
-2.08%
 
ASTRAZEN.NS AstraZeneca Pharma India Limited
9,790.00
-0.95%
 
VENUSREM.NS Venus Remedies Limited
430.00
-1.29%
 
GLAND.NS Gland Pharma Limited
1,642.00
+0.51%
 
UNICHEMLAB.NS Unichem Laboratories Limited
592.90
-0.51%
 
WOCKPHARMA.NS Wockhardt Limited
1,505.40
-1.54%
 
COHANCE.NS COHANCE LIFESCIENCES LTD
1,055.10
-0.81%